Tarsus Pharmaceuticals, Inc. (TARS) Earning

$48.09

north_east
$1.62 (3.49%)
Day's range
$45.6
Day's range
$48.21
TARS Earnings Estimates and Actuals by Quarter$1$1$0$0-$1-$1-$2-$2Q1 2021Q1 2021Q4 2021Q4 2021Q3 2022Q3 2022Q3 2023Q3 2023Q2 2024Q2 2024Q1 2025Q1 2025Q4 2025Q4 2025Q3 2026Q3 2026
Actual EPS
Download SVG
Download PNG
Download CSV

Tarsus Pharmaceuticals, Inc. Analyst EPS Estimates

Quarter Number of Estimates Low Estimate High Estimate Average Estimate
Q1 2025 2 -$0.84 -$0.76 -$0.81
Q2 2025 1 -$0.54 -$0.44 -$0.48
Q3 2025 1 -$0.43 -$0.35 -$0.39
Q4 2025 1 -$0.15 -$0.12 -$0.14
Q1 2026 1 -$0.03 -$0.03 -$0.03
Q2 2026 1 $0.17 $0.21 $0.19
Q3 2026 1 $0.30 $0.37 $0.33
Q4 2026 1 $0.43 $0.53 $0.47

Tarsus Pharmaceuticals, Inc. Earnings Date And Information

Tarsus Pharmaceuticals, Inc. last posted its earnings results on Tuesday, February 25th, 2025. The company reported $-0.6 earnings per share for the quarter, topping analysts' consensus estimates of $-0.68 by $0.08. The company had revenue of 66.41 M for the quarter and had revenue of 182.95 M for the year. Tarsus Pharmaceuticals, Inc. has generated $-3 earnings per share over the last year ($-3.07 diluted earnings per share) and currently has a price-to-earnings ratio of -15.65. Tarsus Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based on prior year's report dates.

Tarsus Pharmaceuticals, Inc. Earnings History by Quarter

Date Quarter Consensus Estimate Reported EPS Beat/Miss Revenue Estimate Actual Revenue
02/25/2025 Q4 2024 -$0.68 -$0.61 0.07 $58.80 M $66.41 M
11/13/2024 Q3 2024 -$0.94 -$0.61 0.33 $43.18 M $48.12 M
08/08/2024 Q2 2024 -$0.98 -$0.88 0.1 $32.33 M $40.81 M
05/08/2024 Q1 2024 -$1.15 -$1.01 0.14 N/A $27.61 M
02/27/2024 Q4 2023 -$1.37 -$1.31 0.06 $5.47 M $13.08 M
11/09/2023 Q3 2023 -$1.40 -$1.28 0.12 $399,560 $1.87 M
08/10/2023 Q2 2023 -$1.08 -$1.17 -0.09 N/A $15.28 M
05/09/2023 Q1 2023 -$0.95 -$0.82 0.13 N/A $2.50 M
03/16/2023 Q4 2022 N/A -$0.49 N/A N/A $10.00 M
11/09/2022 Q3 2022 -$0.98 -$0.84 0.14 $3.50 M $0
08/11/2022 Q2 2022 -$0.65 -$0.26 0.39 $11.25 M $15.28 M
05/11/2022 Q1 2022 N/A -$0.98 N/A N/A $539,000
03/14/2022 Q4 2021 -$0.77 -$0.72 0.05 N/A $338,000
11/10/2021 Q3 2021 N/A -$0.76 N/A $5.33 M $1.24 M
08/04/2021 Q2 2021 N/A $0.31 N/A $4.53 M $22.02 M
05/11/2021 Q1 2021 -$0.64 $0.51 1.15 N/A $33.43 M
03/31/2021 Q4 2020 -$0.66 -$0.56 0.1 N/A $0
11/24/2020 Q3 2020 N/A -$0.54 N/A N/A $0
06/29/2020 Q2 2020 N/A -$0.30 N/A N/A $0
03/30/2020 Q1 2020 N/A -$0.18 N/A N/A $0

Tarsus Pharmaceuticals, Inc. Earnings: FAQ's

Tarsus Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based offlast year's report dates.

In the previous quarter, Tarsus Pharmaceuticals, Inc. (:TARS) reported $-0.6 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.68 by $0.08.

The conference call for Tarsus Pharmaceuticals, Inc.'s latest earnings report can be listened to online.

The conference call transcript for Tarsus Pharmaceuticals, Inc.'s latest earnings report can be read online.

Tarsus Pharmaceuticals, Inc. (:TARS) has a recorded annual revenue of $182.95 M.

Tarsus Pharmaceuticals, Inc. (:TARS) has a recorded net income of $-115,554,000.Tarsus Pharmaceuticals, Inc. has generated $-3.07 earnings per share over the last four quarters.

Tarsus Pharmaceuticals, Inc. (:TARS) has a price-to-earnings ratio of -15.65 and price/earnings-to-growth ratio is -0.85.

Portfolio Sync
Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED